Brief: Adaptimmune Therapeutics Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement
31/01/2023 23:03
Jan 31 (Reuters) - Adaptimmune Therapeutics PLC
ADAP.O :
* ADAPTIMMUNE THERAPEUTICS- ON JAN 27, RECEIVED NOTICE OF
TERMINATION OF AMENDED & RESTATED RESEARCH COLLABORATION &
LICENSE AGREEMENT DATED JAN 13, 2020
* ADAPTIMMUNE THERAPEUTICS- NOTICE TO TERMINATE AGREEMENT
DATED
JAN 13, 202 BETWEEN UNIVERSAL CELLS AND ADAPTIMMUNE LIMITED
Further company coverage: ADAP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptimmune Therapeutics
See all newsAdaptimmune Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview
Enters Settlement Agreement With MD Anderson - SEC Filing
Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 12 cents a share - Earnings Preview